For the quarter ending 2025-09-30, TGTX made $161,709K in revenue. $390,895K in net income. Net profit margin of 241.73%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 161,709 | 141,148 | 85,830 | 83,879 |
| Cost of revenue | 28,093 | 18,938 | 10,421 | 9,341 |
| Noncash compensation | 5,335 | 4,318 | 2,806 | 3,028 |
| Other research and development | 35,543 | 27,464 | 25,493 | 17,110 |
| Total research and development | 40,878 | 31,782 | 28,299 | 20,138 |
| Noncash compensation | 12,351 | 12,044 | 7,837 | 8,745 |
| Other selling, general and administrative | 51,022 | 43,541 | 28,934 | 33,221 |
| Total selling, general and administrative | 63,373 | 55,585 | 36,771 | 41,966 |
| Total costs and expenses | 132,344 | 106,305 | - | - |
| Operating income | 29,365 | 34,843 | 10,340 | 12,434 |
| Interest expense | 6,721 | 6,716 | 4,610 | 10,832 |
| Other income | 3,265 | 2,793 | 1,658 | 2,666 |
| Total other expense, net | -3,456 | -3,923 | -2,952 | -8,166 |
| Net income before taxes | 25,909 | 30,920 | 7,388 | 4,268 |
| Income tax benefit (expense) | -364,986 | 2,733 | 1,076 | 388 |
| Net income | 390,895 | 28,187 | 6,312 | 3,880 |
| Basic (in dollars per share) | 2.69 | 0.19 | 0.04 | 0.03 |
| Diluted (in dollars per share) | 2.43 | 0.17 | 0.045 | 0.02 |
| Us-gaap_weightedaveragenumberofdilutedsharesoutstanding | 160,997,977 | 162,559,404 | -79,900,954 | 160,714,388 |
| Weighted-average common shares outstanding (in shares) | 145,416,901 | 146,739,833 | -72,256,271.5 | 145,102,479 |
TG THERAPEUTICS, INC. (TGTX)
TG THERAPEUTICS, INC. (TGTX)